Table 3

Therapy and response to treatment of immune checkpoint inhibitor-induced arthritis

PatientTherapy: 1=intra-articular GC, 2=systemic GCIncrease in disease activity after GC taperNRS patient before therapyNRS physician before therapyNRS patient after therapyNRS physician after therapy
11, 2, MTX+ve7,57,51,00,5
21NA8,025,00,5
32−ve6,543,51
41, 2, MTX+ve8,072,51
52, MTX+ve9,08,51,01,5
61, 2, MTX+ve7,041,00,5
72, MTX+ve6,02,50,00,5
81NA7,02,51,01,5
91NA8,521,50,5
10NSAIDNA6,53,51,50,5
111, 2, MTX, SSZ+ve6,05,53,52
12NSAIDNA5,533,01
131, 2−ve8,072,52,5
142NA8,04,51,50,5
  • GC, glucocorticoid (shoulders injections usually performed subacromial); MTX, methotrexate; NA, not applicable (no systemic GC received; no follow-up after GC-taper for patient 14 yet available); NRS, numeric rating scale; NRS physician, mean of the NRS values from two expert rheumatologists before and after anti-inflammatory treatment for each patient; NSAID, non-steroidal anti-inflammatory drugs; SSZ, sulfasalazine; +ve, if positive; −ve, if negative.